Retinoblastoma is the prototype genetic cancer: in one or both eyes of young children, most retinoblastomas are initiated by biallelic mutation of the retinoblastoma tumor suppressor gene, RB1, in a developing retinal cell. All those with bilateral retinoblastoma have heritable cancer, although 95% have not inherited the RB1 mutation. Nonheritable retinoblastoma is always unilateral, with 98% caused by loss of both RB1 alleles from the tumor, whereas 2% have normal RB1 in tumors initiated by amplification of the MYCN oncogene. Good understanding of retinoblastoma genetics supports optimal care for retinoblastoma children and their families. Retinoblastoma is the first cancer to officially acknowledge the seminal role of genetics in cancer, by incorporating "H" into the eighth edition of cancer staging (2017): those who carry the RB1 cancer-predisposing gene are H1; those proven to not carry the familial RB1 mutation are H0; and those at unknown risk are HX. We suggest H0* be used for those with residual <1% risk to carry a RB1 mutation due to undetectable mosaicism. Loss of RB1 from a susceptible developing retinal cell initiates the benign precursor, retinoma. Progressive genomic changes result in retinoblastoma, and cancer progression ensues with increasing genomic disarray. Looking forward, novel therapies are anticipated from studies of retinoblastoma and metastatic tumor cells and the second primary cancers that the carriers of RB1 mutations are at high risk to develop. Here, we summarize the concepts of retinoblastoma genetics for ophthalmologists in a question/answer format to assist in the care of patients and their families.
R etinoblastoma is the most common childhood intraocular malignancy that affects one or both eyes.
1 Because of the strong links between clinical care and genetic causation, 2 retinoblastoma is considered the prototype of heritable cancers.
3 Worldwide, about 8000 children are newly diagnosed with retinoblastoma every year (1/16,000 live births) 1,4 but most have no access to knowledge of the important role genetics plays in many aspects of retinoblastoma: clinical presentation, choice of treatment modalities, and follow-up for both child and family. We now highlight the genetic etiology of retinoblastoma in the context of individual children and families, led by the questions commonly asked by parents.
What Is RetInoblastoma?
Retinoblastoma is a cancer that arises because both copies of the RB1 gene that normally suppresses retinoblastoma are lost from a developing retinal cell in fetuses, babies, and young children. Retinoblastoma can affect one (unilateral) or both eyes (bilateral) and, in 5% of children with heritable retinoblastoma (H1), 5 is associated with a midline brain tumor (trilateral). 6 Without timely and effective treatment, retinoblastoma may spread through the optic nerve to the brain, or via blood, particularly to bone marrow, and result in death.
hoW Can CanCeR oCCuR at suCh a Young age?
The cell of origin of retinoblastoma is most likely a developing cone photoreceptor precursor cell that has lost both alleles of the RB1 tumor suppressor gene and remains in the inner nuclear layer of the retina (Fig. 1) , perhaps because it is unable to migrate to the outer retina and function normally. 1, 7, 8 The cell susceptible to developing cancer is present in the retinas of young children, from before birth, up to around 7 years of age. Rarely, retinoblastoma is first diagnosed in older persons, who likely previously had an undetected small tumor (retinoma) present from childhood that later became active. 9, 10 In high-income countries, the mean age at presentation is 12 months in bilateral disease and 24 months in unilateral disease, whereas significant delay in low-income countries impacts negatively on the children.
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What Causes RetInoblastoma?
No one knows what really causes the genomic damage to the RB1 gene, but retinoblastoma arises at a constant rate in all races irrespective of local environment. In nearly 50% of patients, the first copy of the RB1 gene is damaged in most, or all, normal cells of the patient. A retinal tumor develops when the second copy of the RB1 gene is also damaged in a developing retinal cell. 1 The RB1 gene resides on chromosome 13q14 and encodes the retinoblastoma protein (pRB), an important regulator of cell division cycle in most cell types, and the first tumor suppressor gene discovered. 12 Normally, cell division is inhibited by hypophosphorylated pRB binding to E2F molecules and blocking their transactivation of RB1, E2F, and other promoters of molecules that support cell division. [13] [14] [15] To resume cell division, cyclindependent kinases re-phosphorylate pRB, activating promoters of key proteins important in cell division. 16 Loss of pRB therefore allows uncontrolled cell division. In many cell types, loss of the RB1 gene is compensated by increased expression of other related proteins. However, in susceptible cells such as retinal cone cell precursors, compensatory mechanisms are insufficient, allowing uncontrolled cell division to initiate cancer.
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What Causes RetInoblastoma to be unIlateRal veRsus bIlateRal?
In heritable retinoblastoma (also called germline retinoblastoma), the first RB1 allele is mutated (M1) in nearly all cells, including germline reproductive cells, whereas the second allele is mutated (M2) in the retinal cells that become cancer, usually in both eyes (Figs. 2A, B) . The most common M2 event is loss of the normal RB1 allele and duplication of the mutated M1 allele, in that 2 copies of the mutated RB1 gene remain; a mutational event referred to as loss of heterozygosity (LOH).
17,18 Heritable retinoblastoma encompasses 45% of all reported cases 19-21 with bilateral (80%), unilateral (15%), or trilateral (5%) tumors.
1 Germline RB1 mutations carry the risk of second primary cancers, most commonly leiomyosarcoma, osteosarcoma, and melanoma.
22 These patients may benefit from regular surveillance for such cancers over their lifetime.
Of nonheritable retinoblastoma, 98% have both RB1 M1 and M2 events within a retinal cell. In the remaining 2%, retinoblastoma is induced by somatic amplification of the MYCN oncogene, in the presence of normal RB1 genes. 23 fIguRe 1. Early awareness of risk for retinoblastoma optimizes therapy and outcomes. This child was examined because his sibling (triplets) presented with retinoblastoma. His right eye appeared normal, but optical coherence tomography (OCT) revealed 2 invisible tumors (* and ↓) (A-C), which were treated with laser therapy only; OCT after laser shows coagulation of tumors, visible in the retinal image (D-F).
What Caused these mutatIons? dId I Cause them?
No one is to blame for the mutations causing retinoblastoma. Many environmental forces induce DNA damage, including cosmic rays, X-rays, DNA viruses, ultraviolet irradiation, and smoking. The DNA damage may be point mutations, small and large deletions, promotor methylation shutting down RB1 expression, and rarely, chromothripsis. 24, 25 The majority of RB1 mutations arise de novo, unique to a specific patient or family (Fig. 2B) . However, some recurrent mutations are found in unrelated individuals, such as those that affect 11 hyper-mutable CpG DNA sequence sites, which make up 22% of all RB1 mutations. 26, 27 A de novo RB1 germline mutation may arise either pre-or post-conception. Pre-conception mutagenesis of RB1 usually occurs during spermatogenesis, perhaps because cell division (an opportunity for mutation) is very active during spermatogenesis but not during oogenesis. 28, 29 Advanced paternal age increases risk for retinoblastoma, 30 suggesting that genomic errors may increase in aging men. The affected child carries the de novo RB1 mutation in every cell, typically presenting with 4-5 tumors and bilateral retinoblastoma. In contrast, if mutagenesis occurs postconception, during embryogenesis, only a portion of cells will carry the RB1 mutation (ie, mosaicism).
There are 2 answers to this question: (i) loss of both RB1 alleles only causes retinoma, a benign precursor to retinoblastoma, and other genes are modified to cause progression to cancer; 10 and (ii) 2% of unilateral retinoblastoma have normal RB1 and are caused by a different gene.
(i) Retinoma is a premalignant precursor to retinoblastoma with characteristic clinical features: translucent white mass, reactive retinal pigment epithelial proliferation, and calcific foci.
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Retinoma may be found retrospectively after a child develops retinoblastoma (Figs. 2C, 3) . Pathology of retinoma reveals nonproliferative fleurettes. 10, 31 Comparison of adjacent normal retina, retinoma, and retinoblastoma showed loss of both RB1 alleles and early genomic copy number changes in retinoma that were amplified further in the adjacent retinoblastoma.
10 Many retinoblastomas have underlying elements of retinoma. Retinoma can transform to retinoblastoma even after many years of stability, so they need lifelong monitoring. The alternate, confusing term "retinocytoma" was proposed 1 year later 32 and is inappropriate because it had been used for several different entities, including active tumors with Flexner-Wintersteiner rosettes. [33] [34] [35] [36] In addition to loss of RB1, specific alterations in copy number of other genes are common in RB1 -/-retinoblastoma. There are gains (4-10 copies) in oncogenes MDM4, KIF14 (1q32), MYCN (2p24), DEK, and E2F3 (6p22) and loss of the tumor suppressor gene CDH11 (16q22-24).
3,37 Other less common genomic alterations in retinoblastoma tumors include differential expression of specific microRNAs, 38 recurrent single nucleotide variants/insertion-deletions in the genes BCOR and CREBBP, 39 and upregulation of spleen tyrosine kinase (SYK). 40 In comparison with the genomic fIguRe 2. Pedigrees illustrating inheritance patterns for RB1 mutations. A, Full penetrance and expressivity for null mutation: father (bilaterally enucleated) and 2/2 bilaterally affected offspring (I-1 unilateral enucleation vision 1.0 remaining eye); all H1 with 11 base pair deletion in exon 12; DER = 2. B, No family history, new null mutation: triplets 1 diagnosed with bilateral retinoblastoma at age 2.5 months due to c.1345G>T (p.Gly449Ter) RB1 missense mutation resulting in no pRB; parents showed no evidence of the mutation but were considered H0* because there remains a less than 1% risk of mosaicism in either parent; older sibling is negative for the mutation, therefore H0; DER = 2. C, 100% penetrance and variable expressivity: grandfather (I-1) was diagnosed with bilateral retinoma when his daughter (II-1) was diagnosed with bilateral retinoblastoma due to c.1960G>T (p.Val654Leu) RB1 missense mutation; she (II-1) later developed meningioma in the radiation field and breast cancer; her brother (II-3) and daughter (III-2) inherited the mutation and developed unilateral retinoblastoma; DER = 1.5. D, Parent of origin low penetrance 62 : c.607+1G>T RB1 splice mutation that shows higher penetrance when inherited from the father (ie, II-1, III-1, III-3; DER = 1) than from the mother (ie, III-1, III-3; DER = 0), likely due to increased expression from the maternal than the paternal mutant RB1 allele 60 (overall DER = 0.7); IV-1 had a small unilateral tumor but died at 11 years of age due to radiation-induced secondary malignancies; IV-5 has not been tested but developed thyroid cancer.
landscape of other cancers, retinoblastoma is one of the least mutated, and epigenetic modification of gene expression may play an important role in retinoblastoma progression.
39-41 SYK is a postulated methylating proto-oncogene required for retinoblastoma cell survival. It was found to be upregulated in retinoblastoma and suggested as a potential target of therapy. 40, 42 It was present in 100% of retinoblastomas and 0% of normal retina histologically by immunohistochemical staining of pathological specimens of enucleated eyes with retinoblastoma.
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(ii) There is a newly recognized form of retinoblastoma with normal RB1 genes. Two percent of unilateral patients have RB1
A tumors, in which the MYCN oncogene is amplified (28-121 DNA copies instead of the normal 2 copies).
23 These children are diagnosed at a median age of 4.5 months compared with 24 months for nonheritable unilateral RB -/-patients, and the tumors are histologically distinct with advanced features at diagnosis. by tumor. Facial features and various degrees of hypotony and mental retardation in 13q deletion syndrome can lead to discovery of retinoblastoma. 44, 45 If we examine the retina of patients with positive familial history early, we may discover the smallest visible tumors that are round, white retinal lesions that obscure the underlying choroidal pattern; invisible definitive tumors can be detected even earlier by optical coherence tomography (Fig. 1) . 46, 47 Centrifugal growth results in small tumors being round; more extensive growth produces lobular growth, likely related to genomic changes in single (clonal) cells that provide a proliferative advantage. 48 Next, tumor seeds spread out of the main tumor into the subretinal space or vitreous cavity. Vitreous seeding is associated with loss of chromosome 16q, including the cadherin 13 gene, a genomic change that may induce poor cohesive forces between tumor cells. 49, 50 Advanced vitreous tumor seeds can migrate to the anterior chamber producing a pseudohypopyon. Enlarging tumor can push the iris lens diaphragm forward causing angle closure glaucoma. Advanced tumors may induce iris neovascularization. Rapid necrosis of tumor can cause an aseptic orbital inflammatory reaction resembling orbital cellulitis, sometimes showing central retinal artery occlusion on pathology.
48,51 Untreated, retinoblastoma spreads into the optic nerve and brain, or hematogenous spread occurs through choroid, particularly to grow in bone marrow. Tumor extension through sclera can present as orbital extension and proptosis.
do all affeCted IndIvIduals WIth RB1 mutatIons develop RetInoblastoma?
Depending on the exact RB1 mutation, most, but not all, carriers of an RB1 mutation will develop retinoblastoma and other cancers throughout life.
Each offspring of a person carrying an RB1 mutated gene has 50% risk to inherit the RB1 mutated gene (Fig. 2) . A measure of expressivity of a mutant retinoblastoma allele is the diseaseeye ratio (DER) (number of eyes affected with tumor divided by the number of carriers of the RB1 mutation). 52 Nonsense and frame-shift germline mutations that lead to absent or truncated dysfunctional pRB result in 90% bilateral retinoblastoma (nearly complete penetrance, DER = 2). Partially functional RB1 mutated alleles show variable penetrance and expressivity ( Fig. 2C ) with fewer tumors and later onset, 47 and some carriers never develop retinoblastoma (DER = 1-1.5). Reduced penetrance mutated RB1 alleles include (i) mutations in exons 1 and 2, 53 (ii) mutations near the 3' end of the gene in exons 24 to 27, 54,55 (iii) splice and intronic mutations, 56 and (iv) missense mutations. 57 Counterintuitively, large deletions encompassing the RB1 gene and MED4 gene also cause reduced expressivity/penetrance because RB1 -/-cells cannot survive in the absence of MED4 58 and the most common M2 event in retinoblastoma tumors is loss of the normal allele and reduplication of the mutated allele. In comparison, patients with large deletions with 1 breakpoint inside the RB1 gene typically present with bilateral disease.
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There are at least 2 specific RB1 mutant alleles showing a parent-of-origin effect: c.607+1G>T substitution 60, 61 (Fig. 2D ) and c.1981C>T (p.Arg661Trp) missense mutation.
62 Both may be explained by differential methylation of intron 2 CpG85, which skews RB1 expression in favor of the maternal allele. 63 When the mutated allele is maternally inherited, there is sufficient tumor suppressor activity to limit retinoblastoma development to 10% of carriers. However, when the mutated RB1 allele is paternally transmitted, very little pRB is expressed, leading to retinoblastoma in 68% of carriers.
What faCtoRs affeCt RetInoblastoma
CanCeR stagIng?
Treatment and prognosis of retinoblastoma depend on the stage of disease at initial presentation. Factors predictive of outcomes include size, location of tumor origin, extent of subretinal fluid, presence of tumor seeds, and the presence of high-risk features on pathology.
5 Multiple staging systems have predicted likelihood to salvage an eye without using radiation therapy, but published evidence is confusing because significantly different staging versions have been used. 1, 5 The 2017 TNMH classification is based on an international consensus and evidence from an international survey of 1728 eyes and separates well initial clinical and pathological features predictive of outcomes to save the eye, in retrospective comparison with 5 previous eye staging systems. 5 fIguRe 3. Retinoma, the benign precursor of retinoblastoma. Bilateral stable translucent retinal masses with calcification and associate retinal pigment epithelial disturbance were diagnosed to be retinoma in the grandparent I-1 (Fig. 2C) , only when his daughter (II-1) was diagnosed with bilateral retinoblastoma. He never received treatment and was alive and well at age 90 at last follow-up.
does geRmlIne status affeCt RetInoblastoma stagIng?
Retinoblastoma is the first cancer in which staging recognizes the impact of genetic status on outcomes in the 2017 TNMH staging (Fig. 4) : presence of a positive family history, bilateral or trilateral disease, or high sensitivity positive RB1 mutation testing is stage H1; without these features before testing blood, HX; and H0 for those relatives shown to not carry the proband's specific RB1 mutation (Fig. 2) . 5 We propose H0* for patients tested and having neither M1 nor M2 RB1 mutated alleles of the tumor detectable in blood and parents showing no evidence of the M1 allele of their offspring, but with remaining low risk (<1%) of undetectable mosaicism. Offspring of H0* persons who do not show their family's RB1 mutation are H0; if they test H1 for the inherited mutation they need intensive surveillance for eye tumors from birth.
What aRe the maIn goals of RetInoblastoma management?
Saving life is the top priority of retinoblastoma treatment, followed by vision salvage; least important is eye salvage. The child's job is to play and develop over a healthy life; many procedures and their complications that may span years for at best a 50% chance to save a blind eye with risk of tumor spread are not justified, especially when the other eye is normal. 64, 65 Multiple treatment modalities are currently present with promising tumor control in the short term (5 years) with minimal data on their long-term effects. Only after 30 years of being used on every child, the enormous impact of external beam irradiation (EBRT) was recognized: more children with bilateral retinoblastoma who were treated with radiation die of their second (or third, and so on) cancer than of retinoblastoma. 66, 67 However, often missing from choices in the complex care of children with retinoblastoma are truly informed parents. Essentially, the doctors decide what treatment they "feel" is best, based on little substantial evidence. There currently exists no easy way to show the parents prospectively the true "costs" of each treatment: the burden of invasive therapies and potential complications; fIguRe 4. Eighth edition TNMH cancer staging for intraocular retinoblastoma. 54 Clinical staging for eyes with retinoblastoma, compared with IIRC (A).
38 Heritability stage for persons at risk to carry an RB1 germline mutation (B). H0* is our proposal to clarify the remaining small risk of undetectable mosaicism in parents of H1 patients who test negative for the RB1 pathogenic variant in their H1 child and in unilateral patients with no RB1 pathogenic variant detected in blood.
the imposition of hours and days in hospitals and feeling ill on the child, whose real job in those critical, irreplaceable years is to play; the true costs including time off work and uncertainties; and the burden of "false hope" in the absence of real evidence. There are imminent solutions on the horizon: DePICT RB (depictrb.technainstitute.com) collects retinoblastoma-specific details including genetic results and makes them viewable online by the family and patient 68 and the burgeoning field of patient-reported outcomes for research with accurate patient details. These new attitudes and tools may empower, in the future, well-informed choices by parents for their child and family.
What aRe the tReatments and
What goveRns the ChoICe?
Choice of treatment depends on the tumor stage, genetic status, and laterality of disease. Focal therapy can only control cT1a eyes, but visually threatening or large cT1b tumors and cT2 eyes need chemotherapy (systemic or intra-arterial chemotherapy) to reduce the size of the tumor followed by consolidation focal therapies (laser therapy or cryotherapy) as initial treatment. Enucleation of eyes with advanced tumors (cT3) is usually a definitive cure, and if high risk features are found, appropriate treatment response has a chance for cure.
1 Ancillary therapies for specific indications include plaque radiotherapy and periocular chemotherapy. Intravitreal chemotherapy for vitreous disease has recently dramatically improved safe eye salvage. 69 Retinoblastoma with extraocular spread (cT4) requires more aggressive treatments with high dose systemic chemotherapy, surgery, and EBRT with or without autologous stem cell transplantation. For persons carrying RB1 mutations, EBRT is rarely indicated due to the high risk of inducing later second cancers.
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Laterality at presentation also directs treatment choices. In unilateral retinoblastoma, enucleation is the preferred definitive treatment modality if there is anticipated poor visual outcome of the affected eye.
1 If useful vision is anticipated, chemotherapy (systemic or intra-arterial) combined with focal therapy might be utilized. In bilateral retinoblastoma, systemic chemotherapy followed by consolidation focal therapy is preferred when both eyes are salvageable (eighth edition TNMH cancer staging 5 cT1b, cT2) [International Intraocular Retinoblastoma Classification (IIRC) 48 B, C, D eyes]. When one eye is cT1a and the other is advanced, enucleation of the advanced eye and focal therapy for the cT1a eye might be more appropriate. When both eyes are nonsalvageable, bilateral enucleation is the definitive treatment to save life and minimize morbidity.
Is RetInoblastoma lethal?
Untreated, retinoblastoma is lethal. If treated before metastasis occurs, the cure rate is nearly 100%. Occasionally, metastatic retinoblastoma may be confused with a second cancer; molecular demonstration of the RB1 mutations of the intraocular retinoblastoma will confirm metastases. 70 Globally, the chance for cure is remote, and lack of knowledge of genetics results too often in the death of children who could have been saved if they had surveillance and definitive treatment when tumors were small. We look forward to the cancer genomic revolution focusing on metastatic retinoblastoma, leading to breakthrough drugs that make retinoblastoma a zero death cancer. However, delayed diagnosis and treatment due to lack of knowledge by ophthalmologists and parents, along with socioeconomic 64 and cultural factors are the major causes of mortality. Asia and Africa have more than 70% mortality from retinoblastoma compared with less than 5% in developed countries.
hoW Can We test foR RetInoblastoma mutatIons?
Genetic counseling is the psychosocial and educational process to help patients and families adapt to the genetic risk, the genetic condition, and the process of informed decision-making. 72, 73 Especially when genetic testing is not available or unaffordable, genetic counseling is very important. Concrete knowledge of genetic test outcomes supports informed and precise genetic counseling. Genetic testing supports precision medicine for those who need it (carry the RB1 mutated allele) and is more cost effective than examining all at-risk family members. 27, 74 If the proband is bilaterally affected, the probability of finding a germline mutation in the RB1 gene in DNA extracted from blood is high (97% in a comprehensive RB1-specialized laboratory). In 3% of bilateral retinoblastoma patients, the predisposing RB1 mutation cannot be detected in blood. In these instances, identification of M1 and M2 RB1 mutations in DNA from tumor can assist in the identification of a germline mutation, including low-level mosaic mutations. 26, 75, 76 Similarly, to detect the 15% of unilateral patients carrying a germline mutation, the optimal strategy first tests tumor DNA and then looks for the mutations in blood. If the blood is not found to carry 1 of the tumor RB1 mutations, risk of germline status is reduced to less than 1% (Table 1) for parents, siblings, and cousins. 76 Quality of genetic results depends on quality of DNA. Fresh or frozen tumor samples are ideal, whereas DNA from formalin fixed paraffin embedded tumors is suboptimal. Whole blood in EDTA or ACD anticoagulant typically provides high quality DNA.
The RB1 gene can be mutated in many ways, best identified by a series of techniques. The most appropriate technology depends on the clinical question being asked. Next-generation sequencing (NGS) may be the most effective screening strategy to find an unknown de novo mutation in an affected proband and may detect lower level mosaic mutations. 77, 78 To screen family members for a known sequencing-detectable RB1 mutation, targeted Sanger dideoxy sequencing is still more cost and time effective.
Large RB1 deletions or duplications that span whole exons or multiple exons typically cannot be detected by DNA sequencing. Multiplex ligation-dependent probe amplification (MLPA), quantitative multiplex polymerase chain reaction (QM-PCR), or array comparative genomic hybridization (aCGH) are used to identify RB1 deletions and duplications and other genomic copy number alterations, such as MYCN amplification. New developments in bioinformatic analysis methods suggest that NGS data can be interrogated for copy number variants, 77,79 but sensitivity is not yet optimal. Somatic mosaicism can arise in either the presenting patient or their parent. Allele-specific PCR (AS-PCR) has excellent sensitivity when the RB1 mutation is known 26 and can detect as low as 1% mosaicism.
Polymorphic microsatellite markers distributed throughout chromosome 13 can be used to detect a change from a heterozygous state in blood compared with the homozygous state in a tumor with LOH. Microsatellite marker analysis is also important in identity testing and in identifying maternal cell contamination in prenatal samples.
Epigenetic changes can also initiate retinoblastoma development. 80 Hypermethylation of the RB1 promoter CpG island results in inhibition of RB1 gene transcription in 10-12% of retinoblastoma tumors, commonly involving both alleles.
27,81 This epigenetic gene-silencing event primarily occurs in somatic cells, but heritable RB1 promoter mutations and translocations disrupting RB1 regulatory sites or translocations involving the X chromosome have been shown to cause constitutional RB1 promoter hypermethylation.
82,83
Rarely, no RB1 mutation is identified in the coding, promoter, or flanking intronic sequence in blood from a bilateral patient. Deep intronic sequencing alterations that disrupt RB1 transcription by interfering with correct splicing in patients with retinoblastoma can be detected by analysis of the RB1 transcript by reverse transcriptase PCR (RT-PCR).
56,84 RNA studies can also clarify pathogenicity of intronic sequence alterations. As costs decrease, whole genome sequencing may become the method of choice to uncover deep intronic changes.
Karyotype, fluorescent in situ hybridization (FISH), or array comparative genomic hybridization (aCGH) of peripheral blood lymphocytes can be used to identify large deletions and rearrangements in retinoblastoma patients, including patients suspected of 13q14 deletion syndrome. 59 In parents of 13q14 deletion patients, karyotype analysis can be used to investigate for balanced translocations, which increase the risk for retinoblastoma in subsequent generations.
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What Is done afteR fIndIng the RB1 mutatIon?
Family members at risk to also carry the identified RB1 mutation are offered testing on blood samples (Fig. 2, Table 1 ). 1, 76, 85 If the proband's mutation is not found in either parent, a risk for low level mosaicism still exists. Offspring of any family member carrying the RB1 mutation can be tested during pregnancy or immediately after birth. If the proband is mosaic for the RB1 mutation, parents and siblings are not at risk, as mosaicism cannot be inherited. The children of a mosaic proband need to be tested as early as possible because if they do inherit the RB1 mutated allele, they will usually be at high risk of bilateral disease. If they do not carry the mutation, they are at population risk for retinoblastoma.
hoW does the RB1 status affeCt folloW-up of the ChIld?
If the child does not carry an RB1 germline mutation, no examinations under anesthesia (EUAs) are required for the unaffected eye with follow-up only in the clinic (Table 1) . If the child carries a germline mutation or is mosaic for the RB1 mutation, the possibility of new tumors renders frequent EUAs essential up to at least 3 years of age. 86 The germline status also predisposes to other second malignant neoplasms, requiring frequent annual surveillance. The use of whole body magnetic resonance imaging as a method for surveillance is controversial, as a high false positive rate may provoke unnecessary invasive procedures. Development of surveillance programs beyond the pediatric age is a high priority for early detection of these often-lethal second RB1-induced cancers.
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Can We use the KnoWn mutatIon to test mY futuRe ChIldRen?
Prenatal genetic testing can be performed in the course of the pregnancy. Two early procedures are available: (i) chorionic villus sampling (CVS), performed between 11-14 weeks gestation, involves obtaining a sample of the placenta either transvaginally or transabdominally; and (ii) amniocentesis after 16 weeks gestation involves sampling amniotic fluid transabdominally. The procedure-associated risk of miscarriage with CVS is 1%, whereas fIguRe 5. Postnatal diagnosis of familial retinoblastoma too late to save good vision. Bilateral inherited retinoblastoma in a neonate with positive family history born full term (39 weeks) and examined at 5 days after birth: right eye stage cT2b (IIRC group C), left eye stage cT1b (IIRC group B) involving both foveas. Treatment with multiple periocular and systemic chemotherapies and 3 years of focal therapies salvaged both eyes with legal blindness. The child has been previously published (patient #2). 47 amniocentesis is 0.1-0.5%. Maternal cell contamination is more frequent with CVS 87 and is routinely assessed by the clinical molecular lab.
If the fetus does not carry the mutation, the pregnancy can proceed with no further intervention. If the fetus carries the familial mutation, the parents have several choices. Some may decide to stop the pregnancy, whereas others may decide to continue the pregnancy regardless of test results. If the parents are concerned by the risk of miscarriage, they can consider late amniocentesis between 30-34 weeks gestation when the major complication is early delivery rather than miscarriage.
87 Prenatal or postnatal RB1 mutation testing will either show the baby to be H0 (no family RB1 mutation) or H1 (confirmed to carry the mutation). Early preterm delivery of an H1 baby achieves smaller tumors with higher treatment success, eye preservation, and visual outcome than delivery at full term (Fig. 1) . 47 In many countries, the option for prenatal genetic testing is not available, and some parents may choose not to do prenatal invasive testing. All offspring of an H1 parent have a 50% risk for retinoblastoma, so it is important that the pregnancy does not go past 40 weeks (Table 1, Fig. 5 ).
47,76
Can We plan ouR next pRegnanCY to avoId passIng on thIs RB1 mutatIon?
In some countries, preimplantation genetic diagnosis (PGD) with in vitro fertilization is an option. 88 Conceptions are tested for the familial mutation at an early stage of embryonal development (typically at the 8 cell stage). Those that do not carry the RB1 mutation are implanted. The procedure is costly, ranging from $10,000-$15,000 Canadian dollars per cycle; in some countries, there may be full or partial coverage of the costs. The full medical implications of PGD are not yet understood; there is emerging evidence of a low risk for epigenetic changes in the conception as a result of the procedure. It is recommended that typical prenatal testing be pursued during the course of the pregnancy to confirm the results. 88 aRe these tests avaIlable WoRldWIde?
High-sensitivity RB1 mutation testing is established in core labs mainly in high-income countries. 89 In low-and middleincome countries, genetic counseling as a specialty does not exist, so many families with retinoblastoma children do not have the opportunity to understand the benefits of genetic testing and counseling in retinoblastoma treatment and follow-up.
1 In many places, existing health insurance does not cover costs of genetic testing. Given all these obstacles, there is limited application of genetic testing and genetic counseling worldwide, which leads to increased health care to deal with late diagnosis, along with increased economic burden on affected families. As an example, the Chinese government's new policy to allow families to have additional children will make the need for genetic testing and counseling even more important.
In Egypt, genetic testing for retinoblastoma is not available, therefore, genetic counseling is the only way to address the issues facing retinoblastoma families. 90 Ophthalmologists with insufficient training in retinoblastoma genetics are burdened with this task. Genetic counseling was found to decrease knowledge gaps remaining in the translation of this knowledge into appropriate screening action.
ConClusIons
Genetics is a core element in care of retinoblastoma patients and their families. Action based on knowledge of genetics in retinoblastoma improves outcomes for the eye and points to life and treatment strategies that alleviate suffering and may reduce early mortality. 90 The whole family benefits economically in health by precision in diagnosis of risk, based on genetic testing. Treatments accommodate the risks of therapies, and surveillance protocols can achieve earlier diagnosis of retinoblastoma and second cancers, leading to better outcomes. Knowledge of test results alleviates psychological burden on families moving forward with their life choices for the affected child and future siblings and exposure to environmental carcinogens for the whole family.
